News

Amgen has published the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp?? Therapy), a randomised, double-blind and placebo-controlled, phase 3 pivotal study of patients with

Total Nutraceutical Solutions (TNS) has started evaluating several proprietary mushroom compounds for activity in controlling the development of Alzheimer’s Disease (AD). Model Biosystems (MBS) has informed TNS that

CCBR-SYNARC has expaned its Electronic Data Capture (EDC) capabilities for use in imaging clinical trials. With the release of the enhanced SynarcConnect service, SYNARC has further improved its

Xybion Medical, the developer of Pristima, has reported that Calvert Labs has licensed, validated and placed Pristima into production. Using Xybion’s Standard Validation Package to accelerate its implementation

Interleukin will fulfill and process all Inherent Health genetic tests through the company’s CLIA-certified laboratory in Waltham, Massachusetts. Amway Global will assist with marketing, implementation and technical operations

Octapharma Group and Fresenius Kabi have signed a license, development and supply agreement regarding the use of latter’s HESylation Technology to develop a HESylated recombinant protein. Under the

Bikam and Dalton Medicinal Chemistry (Dalton) have renewed their exclusive worldwide collaboration to discover and develop new ophthalmology therapeutics. As per the renewed agreement, Dalton will continue to

Ipsen has launched Dysport in the US for the treatment of cervical dystonia in adults. Dysport is the latest addition to the Ipsen’s drugs already available in North

Daiichi Sankyo has submitted an application in Japan to manufacture and market an injectable preparation of Levofloxacin Hydrate, that incorporates the company’s new quinolone anti-bacterial agent. Reportedly, the